TQ Therapeutics

TQ Therapeutics is a private, preclinical-stage biotech pioneering a novel approach to cell and gene therapy. Its TQx CELLfinity platform, based on the EXiVO method, aims to deliver in vivo therapies that retain the benefits of autologous treatments while overcoming scalability and cost hurdles of ex vivo manufacturing. The company, headquartered in Munich's biotech hub, is focused on oncology and is in the early stages of platform and therapeutic development, positioning itself to address a significant unmet need in advanced cancer treatments. As a young company, it is pre-revenue and likely reliant on venture funding and partnerships to advance its technology.

TQx CELLfinity platform utilizing a proprietary EXiVO approach for the in vivo delivery of cell and gene therapies, aiming to automate and streamline production compared to classical ex vivo methods.

The in vivo cell therapy space is highly competitive, with companies like Capstan Therapeutics, Ensoma, and Umoja Biopharma, as well as large pharma partners, developing various viral and non-viral delivery platforms. TQ must differentiate through its specific EXiVO approach, efficiency, and safety profile to capture value.